HALO compared with GMED: revenue, margins and what each company keeps, and the suppliers and customers both name

HALOHalozyme Therapeutics, Inc.

Mkt capRevenueRevenue

GMEDGlobus Medical Inc

Mkt capRevenueRevenue

Compare

HALOHalozyme Therapeutics, Inc.

GMEDGlobus Medical Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only HALO 32

LLYEli Lilly and Company ("Lilly")customer

ABOSAcumen Pharmaceuticals, Inc. ("Acumen")customer

ARGXargenx BVBA ("argenx")customer

SKYESkye Bioscience, Inc. ("Skye Bioscience")customer

28 more · HALO chain ›

Shared 0

No disclosed counterparties: GMED.

Only GMED 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

HALOHalozyme Therapeutics, Inc.

103.73▼−15.64%· post 104.00

Mkt cap$11.8BRevenue$493MQ3 FY26Revenue$1.4BFY25

GMEDGlobus Medical Inc

70.94▼−12.89%· post 71.30

ClosedNov 6 '26

Mkt cap$10.8BRevenue$764MQ3 FY26Revenue$2.9BFY25

Compare

ClosedNov 6 '26

HALOHalozyme Therapeutics, Inc.

GMEDGlobus Medical Inc

103.73▼−15.64%post 104.00

Price

70.94▼−12.89%post 71.30

$11.8B

Mkt cap

$10.8B

Q3 FY26$493M

Revenue

$764MQ3 FY26

FY25$1.4B

Revenue

$2.9BFY25

HALO103.73▼−15.64%vsGMED70.94▼−12.89%ClosedNov 6 '26